Together with your newly diagnosed
multiple myeloma patients
KEEPING DARZALEX FASPRO®
FRONTLINE
& CENTER
You are a crucial partner
in helping patients learn
more about a proven
frontline treatment with
DARZALEX FASPRO®.
For advanced practice providers (APPs) and nurses
Learn more about how a DARZALEX FASPRO®- or DARZALEX®-based treatment regimen can be a treatment option for a patient with newly diagnosed multiple myeloma.
Combined, DARZALEX FASPRO® and DARZALEX® have a long legacy of proven safety and effectiveness since the initial approval of DARZALEX® in 2015.1,2
Frontline Treatment With DARZALEX FASPRO® and DARZALEX®
DARZALEX FASPRO®/DARZALEX® is the #1 prescribed monoclonal antibody treatment in newly diagnosed multiple myeloma3*
In Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Treat with DRd until disease progression or unacceptable toxicity to give patients the best chance of achieving the results seen in the MAIA trial1
Dosing & Administration
Learn more about the dosing for DARZALEX FASPRO® and DARZALEX®, as well as how they are administered to patients
Mechanism of Action Videos
Daratumumab is a CD38-targeted monoclonal antibody, which is an immunotherapy that works with the immune system. Daratumumab is the main ingredient in DARZALEX FASPRO® and DARZALEX®. You can watch these videos to learn about their mechanisms of action1,2
Additional Resources
You can discover more information or answers to questions you may have about DARZALEX FASPRO® and DARZALEX® by reviewing our additional resources
References:
- DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Data on file. RF-481588. Janssen Biotech, Inc.
